ACRO Biomedical Co., Ltd. (TPEX:6748)

ACRO Biomedical Statistics

Total Valuation

ACRO Biomedical has a market cap or net worth of TWD 4.35 billion. The enterprise value is 3.38 billion.

Market Cap	4.35B
Enterprise Value	3.38B

Important Dates

The next estimated earnings date is Thursday, May 14, 2026.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

ACRO Biomedical has 61.22 million shares outstanding. The number of shares has decreased by -0.40% in one year.

Current Share Class	61.22M
Shares Outstanding	61.22M
Shares Change (YoY)	-0.40%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	16.63%
Owned by Institutions (%)	n/a
Float	43.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	113.62
PB Ratio	3.94
P/TBV Ratio	3.96
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-40.88
EV / Sales	88.33
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-54.66

Financial Position

The company has a current ratio of 51.12, with a Debt / Equity ratio of 0.01.

Current Ratio	51.12
Quick Ratio	49.90
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.17
Interest Coverage	-411.68

Financial Efficiency

Return on equity (ROE) is -9.55% and return on invested capital (ROIC) is -6.56%.

Return on Equity (ROE)	-9.55%
Return on Assets (ROA)	-6.45%
Return on Invested Capital (ROIC)	-6.56%
Return on Capital Employed (ROCE)	-8.29%
Weighted Average Cost of Capital (WACC)	6.47%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	34
Asset Turnover	0.04
Inventory Turnover	1.69

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +81.87% in the last 52 weeks. The beta is 0.41, so ACRO Biomedical's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+81.87%
50-Day Moving Average	65.72
200-Day Moving Average	67.28
Relative Strength Index (RSI)	55.19
Average Volume (20 Days)	438,235

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ACRO Biomedical had revenue of TWD 38.26 million and -82.66 million in losses. Loss per share was -1.35.

Revenue	38.26M
Gross Profit	18.53M
Operating Income	-92.22M
Pretax Income	-82.66M
Net Income	-82.66M
EBITDA	-80.94M
EBIT	-92.22M
Loss Per Share	-1.35

Balance Sheet

The company has 977.87 million in cash and 10.59 million in debt, with a net cash position of 967.28 million or 15.80 per share.

Cash & Cash Equivalents	977.87M
Total Debt	10.59M
Net Cash	967.28M
Net Cash Per Share	15.80
Equity (Book Value)	1.10B
Book Value Per Share	18.04
Working Capital	986.22M

Cash Flow

In the last 12 months, operating cash flow was -49.01 million and capital expenditures -12.82 million, giving a free cash flow of -61.83 million.

Operating Cash Flow	-49.01M
Capital Expenditures	-12.82M
Depreciation & Amortization	11.28M
Net Borrowing	-5.26M
Free Cash Flow	-61.83M
FCF Per Share	-1.01

Margins

Gross margin is 48.43%, with operating and profit margins of -241.06% and -216.06%.

Gross Margin	48.43%
Operating Margin	-241.06%
Pretax Margin	-216.06%
Profit Margin	-216.06%
EBITDA Margin	-211.57%
EBIT Margin	-241.06%
FCF Margin	n/a

Dividends & Yields

ACRO Biomedical does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.40%
Shareholder Yield	0.40%
Earnings Yield	-1.90%
FCF Yield	-1.42%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3